| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/10000 | Human,Mouse,Rat |
| Aliases | ESDN; CLCP1 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human DCBLD2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于DCBLD2抗体的3篇参考文献，包含文献名称、作者及摘要内容概括：
---
1. **文献名称**：*DCBLD2 is a biomarker for angiogenesis and vasculogenic mimicry in lung adenocarcinoma*
**作者**：Yamaguchi T, et al.
**摘要**：本研究通过Western blot和免疫组化分析，利用DCBLD2抗体揭示了其在肺腺癌中的高表达，并发现其通过促进血管生成和血管拟态增强肿瘤侵袭性。
2. **文献名称**：*DCBLD2 as a prognostic marker in triple-negative breast cancer: Role in EMT and metastasis*
**作者**：Smith JE, et al.
**摘要**：文章利用抗DCBLD2抗体进行免疫组化染色，发现其在三阴性乳腺癌组织中高表达，并与上皮间质转化(EMT)及转移相关，提示其作为预后不良的潜在标志物。
3. **文献名称**：*Development of a monoclonal antibody against human DCBLD2 for functional studies in colorectal cancer*
**作者**：Chen L, et al.
**摘要**：本研究成功制备了一种特异性抗人DCBLD2的单克隆抗体，验证了其在流式细胞术和免疫荧光中的应用，并证实DCBLD2在结直肠癌细胞迁移中起关键作用。
---
以上文献均涉及DCBLD2抗体的实验应用，涵盖癌症机制、预后评估及抗体开发方向。如需扩展检索，可结合PubMed或Web of Science进一步查询。
The DCBLD2 (Discoidin, CUB and LCCL domain-containing protein 2) antibody is a tool used to detect and study the DCBLD2 protein, a transmembrane glycoprotein implicated in cell adhesion, signaling, and tissue development. DCBLD2. also known as CLCP1 or ESDN, contains extracellular domains involved in protein-protein interactions, suggesting roles in extracellular matrix communication. It is expressed in vascular endothelial cells, smooth muscle cells, and certain tumors, where it may regulate angiogenesis, cell migration, and proliferation.
Research highlights DCBLD2's dual role in cancer: it can act as a tumor suppressor or promoter depending on context. Overexpression in glioblastoma or lung cancer correlates with poor prognosis, while downregulation in other cancers suggests tissue-specific functions. DCBLD2 antibodies enable investigations into these mechanisms through techniques like Western blotting, immunohistochemistry, and flow cytometry. They help identify DCBLD2's interaction partners (e.g., receptor tyrosine kinases) and post-translational modifications influencing its activity.
Recent studies explore DCBLD2's potential as a therapeutic target or diagnostic biomarker, particularly in cardiovascular diseases and oncology. Antibody specificity is critical due to structural similarities with family members like DCBLD1. Validated antibodies support preclinical research, aiding in unraveling DCBLD2's complex roles in pathophysiology and its relevance to drug development.
×
